Clinical Trials

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04895722 2026-03-30

MK-1308A-008

302 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05763004 2026-03-27

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

140 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT04670679 2026-03-25

FLAGSHP-1

GastrointestinalHead & NeckSarcoma

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Chordoma, Neoplasm Metastasis, Neoplasms, Noonan Syndrome, Colorectal Neoplasms

NCT05555732 2026-03-25

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05838768 2026-03-24

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

123 enrolled

Gastrointestinal

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast

Breast Neoplasms

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05984277 2026-03-17

eVOLVE-Lung02

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast

Breast Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06448312 2026-03-13

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

406 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

GastrointestinalGynecologicThoracic

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.